New AI Algorithm may Improve Autoimmune Disease Prediction and Therapies

A new advanced artificial intelligence (AI) algorithm may lead to better - and earlier - predictions and novel therapies for autoimmune diseases, which involve the immune system mistakenly attacking their body’s own healthy cells and tissues. The algorithm digs into the genetic code underlying the conditions to more accurately model how genes associated with specific autoimmune diseases are expressed and regulated and to identify additional genes of risk.

The work, developed by a team led by Penn State College of Medicine researchers, outperforms existing methodologies and identified 26% more novel gene and trait associations, the researchers said. They published their work in Nature Communications.

"We all carry some DNA mutations, and we need to figure out how any one of these mutations may influence gene expression linked to disease so we can predict disease risk early. This is especially important for autoimmune disease," said Dajiang Liu, distinguished professor, vice chair for research, and director of artificial intelligence and biomedical informatics at the Penn State College of Medicine and co-senior author of the study. "If an AI algorithm can more accurately predict disease risk, it means we can carry out interventions earlier."

Genetics often underpin disease development. Variations in DNA can influence gene expression, or the process by which the information in DNA is converted into functional products like a protein. How much or how little a gene is expressed can influence disease risk.

Genome-wide association studies (GWAS), a popular approach in human genetics research, can home in on regions of the genome associated with a particular disease or trait but can't pinpoint the specific genes that affect disease risks. It’s like sharing your location with a friend with the precise location setting turned off on your smartphone - the city might be obvious, but the address is obscured. Existing methods are also limited in the granularity of its analysis. Gene expression can be specific to certain types of cells. If the analysis doesn’t distinguish between distinct cell types, the results may overlook real causal relationships between genetic variants and gene expression.

The research team's method, dubbed EXPRESSO for EXpression PREdiction with Summary Statistics Only, applies a more advanced artificial intelligence algorithm and analyzes data from single-cell expression quantitative trait loci, a type of data that links genetic variants to the genes they regulate. It also integrates 3D genomic data and epigenetics - which measures how genes may be modified by environment to influence disease - into its modeling. The team applied EXPRESSO to GWAS datasets for 14 autoimmune diseases, including lupus, Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

"With this new method, we were able to identify many more risk genes for autoimmune disease that actually have cell-type specific effects, meaning that they only have effects in a particular cell type and not others," said Bibo Jiang, assistant professor at the Penn State College of Medicine and senior author of the study.

The team then used this information to identify potential therapeutics for autoimmune disease. Currently, there aren't good long-term treatment options, they said.

"Most treatments are designed to mitigate symptoms, not cure the disease. It’s a dilemma knowing that autoimmune disease needs long-term treatment, but the existing treatments often have such bad side effects that they can’t be used for long. Yet, genomics and AI offer a promising route to develop novel therapeutics," said Laura Carrel, professor of biochemistry and molecular biology at the Penn State College of Medicine and co-senior author of the study.

The team's work pointed to drug compounds that could reverse gene expression in cell types associated with an autoimmune disease, such as vitamin K for ulcerative colitis and metformin, which is typically prescribed for type 2 diabetes, for type 1 diabetes. These drugs, already approved by the Food and Drug Administration as safe and effective for treating other diseases, could potentially be repurposed.

The research team is working with collaborators to validate their findings in a laboratory setting and, ultimately, in clinical trials.

Lida Wang, a doctoral student in the biostatistics program, and Chachrit Khunsriraksakul, who earned a doctorate in bioinformatics and geonomics in 2022 and his medical degree in May from Penn State, co-led the study. Other Penn State College of Medicine authors on the paper include: Havell Markus, who is pursuing a doctorate and a medical degree; Dieyi Chen, doctoral candidate; Fan Zhang, graduate student; and Fang Chen, postdoctoral scholar. Xiaowei Zhan, associate professor at UT Southwestern Medical Center, also contributed to the paper.

Funding from the National Institutes of Health (grant numbers R01HG011035, R01AI174108 and R01ES036042) and the Artificial Intelligence and Biomedical Informatics pilot grant from the Penn State College of Medicine supported this work.

Wang L, Khunsriraksakul C, Markus H, Chen D, Zhang F, Chen F, Zhan X, Carrel L, Liu DJ, Jiang B.
Integrating single cell expression quantitative trait loci summary statistics to understand complex trait risk genes.
Nat Commun. 2024 May 20;15(1):4260. doi: 10.1038/s41467-024-48143-1

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...

In 10 Seconds, an AI Model Detects Cance…

Researchers have developed an AI powered model that - in 10 seconds - can determine during surgery if any part of a cancerous brain tumor that could be removed remains...